JenaValve Technology, with operating locations in Munich, Germany and Irvine, California, develops, manufactures and markets transcatheter aortic valve repair (TAVR) systems to treat patients suffering from aortic valve disease. The Company\'s Transapical TAVR system, consisting of the JenaValve valve system plus Cathlete PLUS delivery system, has CE Mark approval for aortic valve stenosis and for the unique indication to treat patients suffering from aortic valve insufficiency. JenaValve currently markets this product in Europe and other selected markets worldwide. JenaValve is backed by world-class U.S., European and Asian investors, including Atlas Venture, Edmond de Rothschild Investment Partners, Gimv (a Euronext-listed investment company - ticker: GIMB), Legend Capital, NeoMed Management, Omega Funds, RMM, Sunstone Capital, Valiance and VI Partners.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/07/15 | $26,500,000 | Series C |
Atlas Venture Edmond de Rothschild Investment Partners GIMV Legend Capital NeoMed Management RMM VI Partners | undisclosed |
| 02/05/20 | $50,000,000 |
Andera Partners Bain Capital  GIMV Legend Capital NeoMed Management RMM Valiance Life Sciences VI Partners | undisclosed |
